학술논문
Results of a randomized, double-blind, placebo controlled, phase 2 study investigating the safety and efficacy of anti-factor XIIa monoclonal antibody garadacimab (CSL312) for prophylaxis of HAE
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15396304